A Phase 2 Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- 04 Oct 2018 Planned End Date changed from 30 Jan 2021 to 10 Sep 2018.
- 04 Oct 2018 Planned primary completion date changed from 30 Jan 2020 to 10 Sep 2018.
- 04 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.